These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28442277)

  • 21. [CLINICAL OUTCOMES OF EXTERNAL-BEAM RADIOTHERAPY COMBINED WITH NEOADJUVANT ANDROGEN DEPRIVATION THERAPY FOR HIGH-RISK PROSTATE CANCER].
    Okada T; Takayama K; Kokubo M; Kono Y; Matsumoto K; Sumiyoshi T; Masuda N; Shiraishi Y; Negoro H; Utsunomiya N; Tsunemori H; Okubo K; Segawa T; Moroi S; Muguruma K; Kawakita M
    Nihon Hinyokika Gakkai Zasshi; 2016; 107(3):162-169. PubMed ID: 28740047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes with brachytherapy based dose escalation for gleason 8 versus 9-10 prostate cancer: An NCDB analysis.
    David J; Luu M; Lu D; Zumsteg ZS; Sandler H; Kamrava M
    Urol Oncol; 2021 Dec; 39(12):829.e19-829.e26. PubMed ID: 34049784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcome for very high-risk prostate cancer treated primarily with a triple modality approach to include permanent interstitial brachytherapy.
    Bittner N; Merrick GS; Butler WM; Galbreath RW; Lief J; Adamovich E; Wallner KE
    Brachytherapy; 2012; 11(4):250-5. PubMed ID: 22436516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.
    Muralidhar V; Mahal BA; Butler S; Lamba N; Yang DD; Leeman J; D'Amico AV; Nguyen PL; Trinh QD; Orio PF; King MT
    J Urol; 2019 Nov; 202(5):973-978. PubMed ID: 31144590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
    Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
    Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Brachytherapy Boost with Overall Survival for Gleason 9-10 Prostate Cancer: The Impact of Primary versus Secondary Pattern 5.
    Patel SA; Baumann B; Michalski J; Brenneman R; Zheng B; Gay H; Ferraro D; Brown SA; Chang AJ; Rossi PJ; Fischer-Valuck BW
    Brachytherapy; 2023; 22(3):310-316. PubMed ID: 36635202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study.
    Sandler KA; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Song DY; Klein EA; Stephenson AJ; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco SC; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR; Kishan AU
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):883-888. PubMed ID: 29976500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.
    Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Shinohara K; Fearn PA; Kattan MW; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):341-6. PubMed ID: 18597953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival Outcomes of Whole-Pelvic Versus Prostate-Only Radiation Therapy for High-Risk Prostate Cancer Patients With Use of the National Cancer Data Base.
    Amini A; Jones BL; Yeh N; Rusthoven CG; Armstrong H; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1052-63. PubMed ID: 26581142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base.
    Amini A; Rusthoven CG; Jones BL; Armstrong H; Raben D; Kavanagh BD
    Urol Oncol; 2016 Apr; 34(4):165.e1-9. PubMed ID: 26699831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of ProCaRS Clinical Nomograms for Biochemical Failure-free Survival Following Either Low-Dose Rate Brachytherapy or Conventionally Fractionated External Beam Radiation Therapy for Localized Prostate Cancer.
    Warner A; Pickles T; Crook J; Martin AG; Souhami L; Catton C; Lukka H; Rodrigues G
    Cureus; 2015 Jun; 7(6):e276. PubMed ID: 26180700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gleason score 7 prostate cancer treated with interstitial brachytherapy with or without supplemental external beam radiation and androgen deprivation therapy: is the primary pattern on needle biopsy prognostic?
    Bittner N; Merrick GS; Butler WM; Galbreath RW; Adamovich E; Wallner KE
    Brachytherapy; 2013; 12(1):14-8. PubMed ID: 22884256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer.
    Muralidhar V; Xiang M; Orio PF; Martin NE; Beard CJ; Feng FY; Hoffman KE; Nguyen PL
    J Contemp Brachytherapy; 2016 Feb; 8(1):1-6. PubMed ID: 26985191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer.
    Rosenberg JE; Chen MH; Nguyen PL; Braccioforte MH; Moran BJ; D'Amico AV
    Clin Genitourin Cancer; 2012 Mar; 10(1):21-5. PubMed ID: 22130293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer.
    Smolska-Ciszewska B; Miszczyk L; Białas B; Fijałkowski M; Plewicki G; Gawkowska-Suwińska M; Giglok M; Behrendt K; Nowicka E; Zajusz A; Suwiński R
    Radiat Oncol; 2015 Mar; 10():60. PubMed ID: 25884489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
    Stromberg JS; Martinez AA; Horwitz EM; Gustafson GS; Gonzalez JA; Spencer WF; Brabbins DS; Dmuchowski CF; Hollander JB; Vicini FA
    Cancer J Sci Am; 1997; 3(6):346-52. PubMed ID: 9403047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of permanent brachytherapy combined with androgen deprivation therapy in an intermediate-risk prostate cancer group without a Gleason score of 4 + 3: a single Japanese institutional experience.
    Okihara K; Kobayashi K; Iwata T; Naitoh Y; Kamoi K; Kawauchi A; Yamada K; Miki T
    Int J Urol; 2014 Mar; 21(3):271-6. PubMed ID: 24033545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection.
    Wattson DA; Chen MH; Moran BJ; Dosoretz DE; Braccioforte MH; Salenius SA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e773-9. PubMed ID: 22300573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.